Table 8.
Therapeutic Index values for the RRWQWR-based peptides against the clinical isolates of HCAI-relevant, Gram- negative bacteria.
| Peptide | Attribute | aHmax | MIC50 (μM) | bGm | cFold | Therapeutic index | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (μM) | Klebsiella pneumoniae | Pseudomonas aeruginosas | MHC/MIC50 | dFold | ||||||||||||
| 49644 | 50181 | 50424 | 51048 | 51009 | 47661 | 48220 | 48221 | 48458 | 48526 | ||||||||
| PLS | Palindromic | 24.8 | 100.0 | 12.5 | 5.6 | 11.7 | 25.6 | 75.0 | 17.4 | 1.8 | 5.8 | 0.6 | |||||
| LfcinB (20–25)2 | Dimeric | 5.6 | 100.0 | 12.3 | 6.6 | 5.8 | 5.7 | 5.6 | 13.4 | 50.0 | 64.2 | 75.0 | 36.3 | 16.8 | 1.7 | 6.0 | 0.6 |
| LfcinB (20–25)4 | Tetrameric | 49.1 | 100.0 | 5.5 | 7.8 | 5.2 | 1.6 | 7.5 | 12.6 | 11.9 | 72.8 | 24.9 | 9.7 | 1.0 | 10.4 | 1.0 | |
a
Hmax: Maximum Hemolytic Activity of the indicated peptide against human erythrocytes after 2 h of treatment at 37°C.
b
GM: geometric mean of the MIC50 values for the indicated peptide against the indicated bacterial strains.
c
Fold: Calculated as (GM for the indicated peptide)/(GM for the tetrameric peptide).
d
Fold: Calculated as (TI for the indicated peptide)/(TI for the tetrameric peptide).